[go: up one dir, main page]

ES2084347T3 - Derivados de 5-heteroil-indol. - Google Patents

Derivados de 5-heteroil-indol.

Info

Publication number
ES2084347T3
ES2084347T3 ES92904837T ES92904837T ES2084347T3 ES 2084347 T3 ES2084347 T3 ES 2084347T3 ES 92904837 T ES92904837 T ES 92904837T ES 92904837 T ES92904837 T ES 92904837T ES 2084347 T3 ES2084347 T3 ES 2084347T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
heteroil
indol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904837T
Other languages
English (en)
Inventor
Jolanta Teresa Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2084347T3 publication Critical patent/ES2084347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Luminescent Compositions (AREA)

Abstract

COMPUESTOS DE FORMULA (I) DONDE R1 ES HIDROGENO, ALKILO C1-C2, FENILO, BENCILO, -COR4, O SO2R4; R2 ES (1), (2) O (3); R3 ES -(CH2)D-Z; Z ES (4); R4 ES ALKILO C1-C6, FENILO, O BENCILO; R5 ES HIDROGENO O ALKILO C1-C6;R6, R7, R11, R12, Y R13, SON CADA UNO INDEPENDIENTEMENTE HIDROGENO O ALKILO C1-C6, O BIEN R8 O R9 ES HIDROGENO, ALKILO C1-C6, ALKILO C1-C6 SUSTITUIDO POR HALOGENO, 1-PIRROLIDINILMETIL, 1-PIPERIDINILMETIL, CICLOPENTILMETIL, CICLOHEXILMETIL O (5) CON EL OTRO SIENDO EL ENLACE ENTRE R3 Y Z; Q ES (6) O (7).
ES92904837T 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol. Expired - Lifetime ES2084347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12

Publications (1)

Publication Number Publication Date
ES2084347T3 true ES2084347T3 (es) 1996-05-01

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904837T Expired - Lifetime ES2084347T3 (es) 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol.

Country Status (24)

Country Link
EP (1) EP0571471B1 (es)
JP (1) JPH07121942B2 (es)
KR (1) KR930703305A (es)
AT (1) ATE135005T1 (es)
AU (1) AU655456B2 (es)
CA (1) CA2101521A1 (es)
CZ (1) CZ165693A3 (es)
DE (1) DE69208868T2 (es)
DK (1) DK0571471T3 (es)
ES (1) ES2084347T3 (es)
FI (1) FI933551L (es)
GR (1) GR3019778T3 (es)
HU (1) HUT65766A (es)
IE (1) IE920442A1 (es)
IL (1) IL100888A0 (es)
MX (1) MX9200569A (es)
MY (1) MY131298A (es)
NO (1) NO932859D0 (es)
NZ (1) NZ241584A (es)
PT (1) PT100114A (es)
TW (1) TW263508B (es)
WO (1) WO1992013856A1 (es)
YU (1) YU13792A (es)
ZA (1) ZA92969B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
EP0765322B1 (en) * 1994-06-01 2001-07-25 AstraZeneca AB Indole derivatives as prodrugs of 5-ht1-like receptor agonists
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
PL322843A1 (en) * 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ATE241615T1 (de) 1998-03-09 2003-06-15 Lundbeck & Co As H 5-heteroaryl-substituierte indole
ATE252572T1 (de) * 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
ES2291024T4 (es) * 1999-04-21 2009-03-01 Nps Allelix Corp. Compuestos de piperidina-indol con afinidad con 5-ht6.
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
AU2003239508A1 (en) 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
DK1581492T3 (da) * 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
MX2007012818A (es) 2005-04-13 2008-01-14 Neuraxon Inc Compuestos indola sustituidos que tienen actividad inhibidora de nos.
AU2006278998A1 (en) * 2005-07-29 2007-02-15 4Sc Ag Novel heterocyclic NF-kB inhibitors
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
CA2643822A1 (en) 2006-04-13 2007-10-25 Neuraxon, Inc 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
WO2008021851A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
US8673909B2 (en) 2007-11-16 2014-03-18 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
WO2013169704A2 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
AU2016344115A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
JP2018531957A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DK0486666T3 (da) * 1990-06-07 1998-03-30 Zeneca Ltd Terapeutisk heterocykliske forbindelser

Also Published As

Publication number Publication date
EP0571471A1 (en) 1993-12-01
ZA92969B (en) 1993-08-11
ATE135005T1 (de) 1996-03-15
JPH06500122A (ja) 1994-01-06
PT100114A (pt) 1993-05-31
FI933551A7 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
AU1263792A (en) 1992-09-07
GR3019778T3 (en) 1996-07-31
HU9302328D0 (en) 1993-10-28
IL100888A0 (en) 1992-11-15
CZ165693A3 (en) 1994-05-18
DE69208868D1 (de) 1996-04-11
DK0571471T3 (da) 1996-04-01
MY131298A (en) 2007-08-30
NZ241584A (en) 1994-12-22
KR930703305A (ko) 1993-11-29
FI933551A0 (fi) 1993-08-11
IE920442A1 (en) 1992-08-12
WO1992013856A1 (en) 1992-08-20
DE69208868T2 (de) 1996-10-17
YU13792A (sh) 1994-11-15
TW263508B (es) 1995-11-21
CA2101521A1 (en) 1992-08-13
HUT65766A (en) 1994-07-28
NO932859L (no) 1993-08-11
EP0571471B1 (en) 1996-03-06
NO932859D0 (no) 1993-08-11
JPH07121942B2 (ja) 1995-12-25
FI933551L (fi) 1993-08-11
MX9200569A (es) 1992-08-01

Similar Documents

Publication Publication Date Title
ES2084347T3 (es) Derivados de 5-heteroil-indol.
ES8603711A1 (es) Procedimiento para preparar compuestos benzimidazoles 2-piridilmetil-tio y sulfinil substituidos
ATE226201T1 (de) Substituierte pyridylpyrazole
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
ATE31307T1 (de) Benzofuran- und benzopyrancarboxamid-derivate.
NZ332559A (en) 3-mercapto-propylamine substituted 4-carbonylamino-5,5-dimethyl-thiazolidine derivatives
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE69813605D1 (de) Benzofuranderivate
NZ528997A (en) Sulfonamides
DK429089D0 (da) Alkylbenzylaminer
UY24010A1 (es) Nuevos pirrolocarbazoles
ES2064618T3 (es) Agonistas de serotonina de tetrahidrobenz(c,d)indol.
ES2121183T3 (es) Ligandos selectivos de los receptores 5ht1d-5ht1b derivados de indol-piperacina utiles como medicamentos.
FI834730A0 (fi) 1-karboxialkanoylperhydro-indol-2-karboxylsyror och deras derivat
NO902336D0 (no) Antispasmotiske midler.
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
AR247735A1 (es) Sulfonildiamidas sustituidas, procedimientos para su preparacion, intermediarios utilizados en el procedimiento, y su utilizacion como herbicidas y reguladoras del crecimiento de las plantas
PT87048A (pt) Process for preparing benzazepine sulfonamides antiarrhythmic agents
ES2092112T3 (es) Agentes hipoglicemicos de tiazolidindiona.
CO4410332A1 (es) Oxazoles y tiazoles sustituidos
ATE41149T1 (de) Substituierte furazane.
US4010175A (en) Thio-{62 -lactam penicillins
ES2097319T3 (es) Derivados de isoxazol como agentes protectores de la luz.
ECSP951529A (es) Compuestos farmaceuticos
ATE130616T1 (de) Stabiles hexahydrat von etoposid-4&#39;-phosphat- dinatriumsalz.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 571471

Country of ref document: ES